New image analytics may offer quick guidance for breast cancer treatment

February 18, 2016
New image analytics may offer quick guidance for breast cancer treatment
Differences in dynamic textural pattern features are apparent between a patient with a low recurrence score, left, and a patient with a high recurrence score, right. Credit: Nature Scientific Reports

For women with the most common type of breast cancer, a new way to analyze magnetic resonance images (MRI) data appears to reliably distinguish between patients who would need only hormonal treatment and those who also need chemotherapy, researchers from Case Western Reserve University report.

The analysis may provide women diagnosed with estrogen positive-receptor (ER-positive) answers far faster than current tests and, due to its expected low cost, open the door to this kind of testing worldwide.

The research is published in the journal Nature Scientific Reports.

"In the United States, nearly 70 percent of all are diagnosed with ER-positive, but the majority don't need chemotherapy," said Anant Madabhushi, biomedical engineering professor at Case Western Reserve and research leader.

"Until about 15 years ago, doctors had no way of telling aggressive cancer from non-aggressive, so the majority of women got chemotherapy, which can produce very harsh side effects," he said.

Since then, a genomic test for differentiating between aggressive and nonaggressive cancer was developed. The test requires doctors to send a biopsy sample to a company that analyzes it and assigns a risk score that the doctors then use to guide treatment.

"The test is used frequently in the United States, but it destroys tissue, requires shipping and costs about $4,000," said Madabhushi, who is a member of the Case Comprehensive Cancer Center. "The cost puts the test out of reach for people in middle- and low-income countries."

Data mining

Madabhushi's team, which employs big data to study disease, thought they might find useful signals to discern aggressive ER-positive from indolent by mining radiologic data from MRIs.

They analyzed images of 96 ER-positive cancer scanned at a hospital in Cleveland or Boston. Each woman had undergone what's called a "dynamic contrast enhanced MRI," which produces images of tissues as they take up a contrast agent. Each woman had also undergone the genomic test.

Because intensity values regularly used to analyze tissues vary by scanner, the researchers needed a different way to search for signals distinguishing the two categories of patients.

  • They discovered differences in gene expression—molecular changes that appeared as changes in textural patterns in the images.
  • They converted the dynamic texture changes into quantitative measurements and used differences in the measurements to determine which patients needed chemotherapy and which did not.

In 85 percent of the cases, the conclusions matched those of the genomic test.

"We think the dynamic texture data is robust and reliable," Madabhushi said. "It allows us to compare apples to apples."

Potential advantages

He expects the test, if further trials validate it, would cost "pennies on the dollar, compared to the $4,000 test."

For the patient, the test requires an MRI scan, which many doctors already prescribe for those newly diagnosed with cancer. "So the test, for many, doesn't require the cost of a scan," Madabhushi said.

He said a computer and program are the tools needed. No tissue would be shipped. Instead of waiting a week or two for results, the wait would be minutes, reducing the stress on patients and allowing them to quickly start treatment, the researchers say.

"With cloud computing and data warehousing, we can analyze images coming in from anywhere in the world, "Madabhushi said. "It breaks down geographic boundaries because everything is electronically transmitted."

The researchers are seeking funding to evaluate the test further. They want to look at the outcomes for the 96 patients to try to determine how accurately this test and the genomic test predicted who needed chemotherapy and who didn't. They plan to test scans from more sites to see if the results hold up.

Madabhushi said even if the MRI test proves to make accurate predictions only for patients at extremely low or extremely high need for chemotherapy, the analysis would still serve 30 to 40 percent of patients.

Explore further: Researchers building digital pathology tools to predict cancer outcomes

More information: Tao Wan et al. A Radio-genomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores, Scientific Reports (2016). DOI: 10.1038/srep21394

Related Stories

Researchers building digital pathology tools to predict cancer outcomes

November 11, 2015
Case Western Reserve University researchers have been awarded two grants totaling $3.16 million from the National Institutes of Health (NIH) to create analytic software for managing, annotating, sharing and analyzing digital ...

Using big data to identify triple-negative breast, oropharyngeal, and lung cancers

March 18, 2014
Researchers at Case Western Reserve University and colleagues used "big data" analytics to predict if a patient is suffering from aggressive triple-negative breast cancer, slower-moving cancers or non-cancerous lesions with ...

One in five women with breast cancer don't know about test results that might help them avoid chemo

May 29, 2015
Although 90 percent of women with early-stage breast cancer said they were aware they took a genomic test that identified their level of risk for a recurrence of the disease, one in five didn't know the results of that analysis, ...

New study could save breast cancer patients time, money and side effects

October 22, 2015
Most breast cancer patients with invasive lobular carcinoma could be treated with hormones alone and not with chemotherapy, according to a study by Virginia Piper Cancer Institute at Abbott Northwestern Hospital, part of ...

New breast cancer test will help more women avoid unnecessary chemotherapy

July 3, 2013
A new genetic test for one of the most common forms of breast cancer will help doctors better identify those women who should be considered for chemotherapy, and those who can avoid it, say researchers.

21-gene recurrence score and receipt of chemotherapy in patients with breast cancer

August 27, 2015
Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test among a large group of Medicare ...

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.